Bone marrow inhibition induced by azathioprine in a patient without mutation in the thiopurine S-methyltransferase pathogenic site:A case report  

作　　者：Xiao-Shuang Zhou Yuan-Yue Lu Yan-Fang Gao Wen Shao Jia Yao 

机构地区：[1]College of Biomedical Engineering,Taiyuan University of Technology,Taiyuan 030012,Shanxi Province,China [2]Department of Nephrology,The Affiliated People's Hospital of Shanxi Medical University,Taiyuan 030032,Shanxi Province,China [3]Department of Gastroenterology,Shanxi Bethune Hospital,Taiyuan 030012,Shanxi Province,China

出　　处：《World Journal of Clinical Cases》2021年第17期4230-4237,共8页世界临床病例杂志

摘　　要：BACKGROUND Azathioprine(AZA)and its close analog 6-mercaptopurine are thiopurines widely used in the treatment of patients with cancer,organ transplantation,and autoimmune or inflammatory diseases,including systemic lupus erythematosus.Bone marrow inhibition is a common side effect of AZA,and severe bone marrow inhibition is related to decreased thiopurine S-methyltransferase(TPMT)activity.CASE SUMMARY We herein report a patient with proliferative lupus nephritis who was using AZA for maintenance therapy,had no common TPMT pathogenic site mutations,and exhibited severe bone marrow inhibition on the 15th day after oral administration.CONCLUSION This report alerts physicians to the fact that even though the TPMT gene has no common pathogenic site mutation,severe myelosuppression may also occur.

关 键 词：AZATHIOPRINE Thiopurine S-methyltransferase Bone marrow inhibition Lupus nephritis Case report 

分 类 号：R969[医药卫生—药理学]